Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,365.91 -51.77 -0.36%
TOPIX 1,163.81 -2.74 -0.23%
HANG SENG 22,731.30 35.29 0.16%

Scancell Hlds SCLP Result of AGM



  Scancell Hlds (SCLP) - Result of AGM

RNS Number : 5880Q
Scancell Holdings Plc
07 November 2012
 

7 November 2012

                            Scancell Holdings Plc

                                 ('Scancell')

                                       

                                 Result of AGM

                                       

 

Scancell Holdings  Plc,  (AIM:  SCLP), the  developer  of  therapeutic  cancer 
vaccines, announces that at  the Annual General  Meeting, held yesterday,  all 
resolutions were duly passed.

 

 

About Scancell

 

Scancell is developing therapeutic  vaccines for the  treatment of cancer  and 
infectious  diseases  based  on  its  ImmunoBody®  and  Moditope™   technology 
platforms. Scancell's first cancer  vaccine SCIB1 is  being developed for  the 
treatment of melanoma.

 

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a  patient, stimulating an  immune response. Effective  cancer 
vaccines need  to  target dendritic  cells  to  stimulate both  parts  of  the 
cellular  immune  system;  the  helper  cell  system  where  inflammation   is 
stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL  response 
where immune system cells are primed to recognise and kill specific cells.

 

A limitation of  many cancer vaccines  currently in development  is that  they 
cannot specifically  target  dendritic  cells in  vivo.  Several  groups  have 
demonstrated successful  vaccination  by  growing  dendritic  cells  ex  vivo, 
pulsing  them  with  tumour  antigens  and  re-infusing  them.  However,  this 
procedure is  patient specific,  time consuming  and expensive.  Scancell  has 
developed its breakthrough patent protected ImmunoBody® technology to overcome
these limitations.

 

Scancell has also identified and patented  a series of modified epitopes  that 
stimulate the production of killer CD4 that destroy tumours without  toxicity. 
The Directors believe that the Moditope™ platform could have a profound effect
on the way that cancer vaccines are developed.

 

The Directors of the issuer accept responsibility for this announcement.

                                       

 

                                    -ENDS-

 

 

 

 


 

For Further Information:             

                                     

Scancell Holdings Plc               + 44 (0) 74 2323 0497 

Dr Richard Goodfellow, Joint CEO     

Professor Lindy Durrant, Joint CEO 
 
Visible Value LLP:                  + 44 (0) 74 2323 0497 

Annie Cheng, CFA                    scancell@visible-value.com
Cenkos Securities:                  +44 (0) 20 7397 8900
Camilla Hume

Stephen Keys

 

 

                                                                                             

 

                     This information is provided by RNS
           The company news service from the London Stock Exchange
 
END
 
 
RAGBUBDBCUGBGDR -0- Nov/07/2012 16:02 GMT
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement